CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Interferon Gamma Release Assay for the Identification of Latent Tuberculosis Infection in Rural and Remote Settings: Clinical Utility, Cost-Effectiveness, and Guidelines

Last updated: August 17, 2020
Project Number: RB1512-000
Product Line: Rapid Response
Research Type: Device
Report Type: Summary of Abstracts
Result type: Report

Question

  1. What is the clinical utility of the interferon gamma release assay for identifying latent tuberculosis infection in rural and remote settings?
  2. What is the cost-effectiveness of the interferon gamma release assay for identifying latent tuberculosis infection in rural and remote settings?
  3. What are the evidence-based guidelines regarding the identification of latent tuberculosis infection in rural and remote settings?

Key Message

One systematic review was identified regarding the clinical utility of the interferon gamma release assay for identifying latent tuberculosis infection in rural and remote settings. No relevant economic evaluations were identified regarding the cost-effectiveness of the interferon gamma release assay for identifying latent tuberculosis infection in rural and remote settings. In addition, no relevant evidence-based guidelines were identified regarding the identification of latent tuberculosis infection in rural and remote settings.